Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct 31;15(5):2353-2357.
doi: 10.21037/jgo-24-376. Epub 2024 Oct 16.

The role of negative hyperselection in metastatic colorectal cancer

Jingran Ji  1 , Marwan Fakih  1
Affiliations
Editorial

The role of negative hyperselection in metastatic colorectal cancer

Jingran Ji et al. J Gastrointest Oncol. .
No abstract available

Keywords: Negative hyperselection; RAS wild type (RAS WT); cetuximab (Cmab); metastatic colorectal cancer (mCRC); panitumumab (Pmab).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-24-376/coif). M.F. serves as an unpaid editorial board member of Journal of Gastrointestinal Oncology from January 2023 to December 2024. M.F. receives consulting fees from AbbVie, Adagene, Bayer, BMS, Delcath, Eisai, Entos, Merck, Mirati, Nouscom, Pfizer, Roche, Tempus, Totus, Taiho, Sanofi and received grants from Agenus, Verastem, Genentech, BMS. The other author has no conflicts of interest to declare.

Comment on

References

    1. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705. 10.1200/JCO.2009.27.4860 - DOI - PubMed
    1. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9. 10.1200/JCO.2010.33.5091 - DOI - PubMed
    1. Yin J, Cohen R, Jin Z, et al. Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. J Natl Cancer Inst 2021;113:1705-13. 10.1093/jnci/djab112 - DOI - PubMed
    1. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol 2017;3:194-201. 10.1001/jamaoncol.2016.3797 - DOI - PMC - PubMed
    1. Loree JM, Pereira AAL, Lam M, et al. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res 2018;24:1062-72. 10.1158/1078-0432.CCR-17-2484 - DOI - PMC - PubMed

LinkOut - more resources